|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Biermann JS, Adkins DR, Agulnik M,
Benjamin RS, Brigman B, Butrynski JE, Cheong D, Chow W, Curry WT,
Frassica DA, et al: Bone cancer. J Natl Compr Canc Netw.
11:688–723. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lindsey BA, Markel JE and Kleinerman ES:
Osteosarcoma overview. Rheumatol Ther. 4:25–43. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Pediatric and adolescent osteosarcoma (US).
Springer. 152:3–13. 2009. View Article : Google Scholar
|
|
6
|
Bacci G, Longhi A, Bertoni F, Briccoli A,
Versari M, Pignotti E and Picci P: Bone metastases in osteosarcoma
patients treated with neoadjuvant or adjuvant chemotherapy. The
Rizzoli experience in 52 patients. Acta Orthopaed. 77:938–943.
2006. View Article : Google Scholar
|
|
7
|
Heyer BS, Warsowe J, Solter D, Knowles BB
and Ackerman SL: New member of the SNF1/AMPK kinase family, Melk,
is expressed in the mouse egg and preimplantation embryo. Mol
Reprod Dev. 47:148–156. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang Y, Zhou X, Li Y, Xu Y, Lu K, Li P
and Wang X: Inhibition of maternal embryonic leucine zipper kinase
with OTSSP167 displays potent anti-leukemic effects in chronic
lymphocytic leukemia. Oncogene. 37:5520–5533. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jiang P and Zhang D: Maternal embryonic
leucine zipper kinase (MELK): A novel regulator in cell cycle
control, embryonic development, and cancer. Int J Mol Sci.
14:21551–21560. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ganguly R, Hong CS, Smith LG, Kornblum HI
and Nakano I: Maternal embryonic leucine zipper kinase: Key kinase
for stem cell phenotype in glioma and other cancers. Mol Cancer
Ther. 13:1393–1398. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Janostiak R, Rauniyar N, Lam TT, Ou J, Zhu
LJ, Green MR and Wajapeyee N: MELK promotes melanoma growth by
stimulating the NF-κB pathway. Cell Rep. 21:2829–2841. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li G, Yang M, Zuo L and Wang MX: MELK as a
potential target to control cell proliferation in triple-negative
breast cancer MDA-MB-231 cells. Oncol Lett. 15:9934–9940.
2018.PubMed/NCBI
|
|
13
|
Kohler RS, Kettelhack H,
Knipprath-Mészaros AM, Fedier A, Schoetzau A, Jacob F and
Heinzelmann-Schwarz V: MELK expression in ovarian cancer correlates
with poor outcome and its inhibition by OTSSP167 abrogates
proliferation and viability of ovarian cancer cells. Gynecol Oncol.
145:159–166. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li S, Li Z, Guo T, Xing XF, Cheng X, Du H,
Wen XZ and Ji JF: Maternal embryonic leucine zipper kinase serves
as a poor prognosis marker and therapeutic target in gastric
cancer. Oncotarget. 7:6266–6280. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gray D, Jubb AM, Hogue D, Dowd P, Kljavin
N, Yi S, Bai W, Frantz G, Zhang Z, Koeppen H, et al: Maternal
embryonic leucine Zipper Kinase/Murine protein serine-threonine
kinase 38 is a promising therapeutic target for multiple cancers.
Cancer Res. 65:9751–9761. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu S, Chen X, Hu C, Wang J, Shen Y and
Zhong Z: Up-regulated maternal embryonic leucine zipper kinase
predicts poor prognosis of hepatocellular carcinoma patients in a
Chinese Han population. Med Sci Monit. 23:5705–5713. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pickard MR, Green AR, Ellis IO, Caldas C,
Hedge VL, Mourtada-Maarabouni M and Williams GT: Dysregulated
expression of Fau and MELK is associated with poor prognosis in
breast cancer. Breast Cancer Res. 11:R602009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chung S and Nakamura Y: MELK inhibitor,
novel molecular targeted therapeutics for human cancer stem cells.
Cell Cycle. 12:1655–1656. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chung S, Suzuki H, Miyamoto T, Takamatsu
N, Tatsuguchi A, Ueda K, Kijima K, Nakamura Y and Matsuo Y:
Development of an orally-administrative MELK-targeting inhibitor
that suppresses the growth of various types of human cancer.
Oncotarget. 3:1629–1640. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu D, Zhang XX, Li MC, Cao CH, Wan DY, Xi
BX, Tan JH, Wang J, Yang ZY, Feng XX, et al: C/EBPβ enhances
platinum resistance of ovarian cancer cells by reprogramming H3K79
methylation. Nat Commun. 9:17392018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen G and Deng X: Cell synchronization by
double thymidine block. Bio Protoc. 8:e29942018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ganguly R, Mohyeldin A, Thiel J, Kornblum
HI, Beullens M and Nakano I: MELK-a conserved kinase: Functions,
signaling, cancer, and controversy. Clin Transl Med. 4:112015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin ML, Park JH, Nishidate T, Nakamura Y
and Katagiri T: Involvement of maternal embryonic leucine zipper
kinase (MELK) in mammary carcinogenesis through interaction with
Bcl-G, a pro-apoptotic member of the Bcl-2 family. Breast Cancer
Res. 9:R172007. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Strzalka W and Ziemienowicz A:
Proliferating cell nuclear antigen (PCNA): A key factor in DNA
replication and cell cycle regulation. Ann Bot. 107:1127–1140.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Müller R, Misund K, Holien T, Bachke S,
Gilljam KM, Våtsveen TK, Rø TB, Bellacchio E, Sundan A and Otterlei
M: Targeting proliferating cell nuclear antigen and its protein
interactions induces apoptosis in multiple myeloma cells. PLoS One.
8:e704302013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang X, Wang D, Yuan N, Liu F, Wang F,
Wang B and Zhou D: The prognostic value of PCNA expression in
patients with osteosarcoma: A meta-analysis of 16 studies. Medicine
(Baltimore). 96:e82542017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jabłońska-Trypuć A, Matejczyk M and
Rosochacki S: Matrix metalloproteinases (MMPs), the main
extracellular matrix (ECM) enzymes in collagen degradation, as a
target for anticancer drugs. J Enzyme Inhib Med Chem. 31 (Suppl
1):S177–S183. 2016. View Article : Google Scholar
|
|
29
|
Viros D, Camacho M, Zarraonandia I, García
J, Quer M, Vila L and León X: Prognostic role of MMP-9 expression
in head and neck carcinoma patients treated with radiotherapy or
chemoradiotherapy. Oral Oncol. 49:322–325. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vilen ST, Salo T, Sorsa T and Nyberg P:
Fluctuating roles of matrix metalloproteinase-9 in oral squamous
cell carcinoma. ScientificWorldJournal. 2013:9205952013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhou J, Liu T and Wang W: Prognostic
significance of matrix metalloproteinase 9 expression in
osteosarcoma: A meta-analysis of 16 studies. Medicine (Baltimore).
97:e130512018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou HY, Yao XM, Chen XD, Tang JM, Qiao ZG
and Wu XY: Mechanism of metformin enhancing the sensitivity of
human pancreatic cancer cells to gem-citabine by regulating the
PI3K/Akt/mTOR signaling pathway. Eur Rev Med Pharmacol Sci.
23:10283–10289. 2019.PubMed/NCBI
|
|
33
|
Ou JM, Qiu MK, Dai YX, Dong Q, Shen J,
Dong P and Fei ZW: Combined Blockade and Akt/mTOR pathway inhibits
growth of human hemangioma via downregulation of proliferating cell
nuclear antigen. Int J Immunopathol Pharmacol. 25:945–953. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Olaisen C, Muller R, Nedal A and Otterlei
M: PCNA-interacting peptides reduce Akt phosphorylation and
TLR-mediated cytokine secretion suggesting a role of PCNA in
cellular signaling. Cell Signal. 27:1478–1487. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dobbin ZC and Landen CN: The importance of
the PI3K/AKT/mTOR pathway in the progression of ovarian cancer. Int
J Mol Sci. 14:8213–8227. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Levine DA, Bogomolniy F, Yee CJ, Lash A,
Barakat RR, Borgen PI and Boyd J: Frequent mutation of the PIK3CA
gene in ovarian and breast cancers. Clin Cancer Res. 11:2875–2878.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Matsuoka T and Yashiro M: The role of
PI3K/Akt/mTOR signaling in gastric carcinoma. Cancers (Basel).
6:1441–1463. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ji W, Arnst C, Tipton AR, Bekier ME II,
Taylor WR, Yen TJ and Liu ST: OTSSP167 abrogates mitotic checkpoint
through inhibiting multiple mitotic kinases. PLoS One.
11:e01535182016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lee JJ, Loh K and Yap YS: PI3K/Akt/mTOR
inhibitors in breast cancer. Cancer Biol Med. 12:342–354.
2015.PubMed/NCBI
|
